Sign In to Follow Application
View All Documents & Correspondence

Process For The Preparation Of Ethyl N (2,3 Dichloro 6 Nitrobenzyl)glycine Hydrochloride

Abstract: The invention relates to a process for the preparation of anagrelide, and for the preparation of intermediates for use in preparing anagrelide. The invention also relates to the inteπnediates per se, in particular compounds of formula (V) where R constitutes a suitable leaving group, which may not be hydrogen. The R group may be is selected from: (i) -SiR13, (ii) -CH2Ar, (iii) -COOR2, and (iv) sulfonates such as -SO2R3.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
16 July 2009
Publication Number
18/2011
Publication Type
INA
Invention Field
NO SUBJECT
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2017-04-13
Renewal Date

Applicants

CIPLA LIMITED
289 BELLASIS ROAD, MUMBAI CENTRAL, MUMBAI 400 008, INDIA

Inventors

1. PATHI SRINIVAS LAXMINARAYAN
2475/24, 7TH B MAIN, R P C LAYOUT, VIJAYNAGAR, BANGALORE 560040, KARNATAKA, INDIA
2. KANKAN RAJENDRA NARAYANRAO
1204, HERITAGE, HIRANANDANI GARDENS, POWAI, MUMBAI 400076, INDIA
3. RAO DHARMARAJ RAMACHANDRA
4/403 GARDEN ENCLAVE, POKHRAN ROAD 2, THANE WEST, MUMBAI 400601, MAHARASHTRA, INDIA

Specification

FORM 2
Process for the Preparation of ethvl-n-(2. 3-dichloro-6-nitrobenzyl) glycine hydrochloride

Field of invention
10 The present invention relates to an improved process for the preparation of ethyl-N-(2, 3-dichloro-6-nitrobenzyl)glycine hydrochloride which is a key intermediate used in the preparation of anagrelide, (6,7-dichloro-l ,5-dihydroimidazo[2,l-b]quinazolin-2(3H)-one.
Background of the invention 15
Anagrelide, is a potent reducer of platelet count induced by a variety of aggregating agents and has the following structure
20
US 4146718 disclose? the process for the preparation of ethyl-N-(2,3-dich!oro-6n:trobenzyl) glycine hydrochloride from 1,2,3-trichlorobenzene as depicted in Scheme I via 2,3-dichloro-6-nitrobenzonitrile, which involves the use of poisonous reagents, such as cuprous cyanide. Cyanation is carried out at a temperature of 165°C which is highly exothermic, uncontrollable
25 and not scalable. 2, 3-dichloro-6-nitrobenzonitrile has extreme toxic and skin-irritant properties. Diborane is a flammable gas, used for the reduction of 2, 3-dichloro-6-nitrobenzonitrile. The reduction reaction is exothermic, uncontrollable and not feasible industrially.
30

WO 2008/096145

PCT/GB2008/000430


10 The reaction involves a radical halogenation of the toluene group. The material is purified by column chromatography at each stage which makes the process more tedious and it is not


WO 2008/096145

PCT/GB2008/000430

viable industrially. The use of a chromatographic solvent, such as chloroform (which is a known carcinogen), is disadvantageous with respect to industrial application.
US 2003/0060630 discloses a method for making ethyl-N-(2, 3-dichloro-6-nitro 5 benzyl)glycine hydrochloride form 2,3-dichloro benzaldehyde as depicted in Scheme III.
Scheme III:

10
In step (b), the reduction reaction is carried out in high boiling solvents like toluene. The reduction in step (b) and the chlorination in step (c) are sluggish. Also, the chlorination reaction is exothermic and uncontrollable, which leads to formation of more impurities and thereby resulting in low yield (page 4, column 2, and page 5, column 1: 65 %) . Hence, this
15 prior art process is not viable for industrial scale up.
Because of the difficulties encountered in the processes disclosed in the prior art, there is a need to develop more efficient and economical synthetic route for the preparation of ethyl-N-
,1 6 JUL 2009

WO 2008/096145

PCT/GB2008/000430

4 (2,3-dichloro-6-nitrobenzy])glycine hydrochloride, which is suitable for industrial scale up. The present invention relates to a new process for the synthesis of Ethyl-N-(2, 3-dichloro-6-nitrobenzyl)glycine hydrochloride.
5 It is an object of the present invention is to provide a novel process for the synthesis of the intermediate ethyl N-(2, 3-dichloro-6-nitrobenzyl)glycine hydrochloride.
Another object of the present invention is to provide novel process for synthesis of anagrelide.
10 Yet, another object of the present invention is to provide a simple novel process which is useful for application on an industrial scale.
Summary of the Invention
15 The present invention provides a new process for the synthesis of ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride, a compound of Formula (I)

which comprises the following steps; 20 (i) reducing 2,3-dichloro-6-nitro benzaldehyde Formula (III),

to form 2,3-dichloro-6-nitro benzyl alcohol of Formula (rV),

1 6 JUL 2009

WO 2008/096145

PCT/GB2008/000430

(ii) reacting 2,3-dichloro-6-rtitro benzyl alcohol with suitable compound to obtain compound of Formula (V),

where R constitutes a suitable leaving group, which may not be hydrogen.
Preferably, the group R is selected from:
10
i) -SiR!3, where R1 is a substituted or unsubstituted alkyl. R1 is preferably C1 to C6,
more preferably C1 to C4 straight or branched chain alkyl group. Most preferably R1 is
methyl.
ii) -CH2Ar, where Ar stands for aryl, preferably a substituted or unsubstituted phenyl
15 group.
iii) -COOR2, where R2 is alkyl or aryl. When R2 is alkyl it is preferably Q to C6, more preferably C1 to C4 straight or branched chain alkyl. When R2 is alkyl, it is most preferably methyl. The aryl group is preferr.h'y a substituted or ".nsubstituted phenyl group.
20 iv) sulfonates such as -SO2R3 , where R3 is alkyl or aryl. When R3 is alkyl it is
preferably C1 to C6, more preferably C1 to C4 straight or branched chain alkyl. When R3 is alkyl, it is most preferably methyl. The aryl group is preferably a substituted or unsubstituted phenyl group.
25 The most preferred -O-R groups in formula (V) are mesylate, besylate and tosylate.
(iii) Alkylating the compound of Formula (V) with glycine ethyl ester in a suitable solvent, using a base, and then converting to a salt, preferably the hydrochoride salt, in a suitable solvent, to obtain compound of Formula I.
16 JUL 2009

WO 2008/096145

PCT/GB2008/000430

It will be appreciated that step (i) is optional, in that the compound of formula (IV) may be provided by any suitable means.
5 Thus, according to one aspect of the invention there is provided a process for the synthesis of a compound of Formula (V)
where R is a suitable leaving group, which may not be hydrogen, said process comprising reacting a compound of formula (IV) 10

with suitable compound to obtain the compound of Formula (V).
15 Preferably, the reaction is carried oat in thr presence of an alkyl or ary sulphonyl halide, especially a methyl sulphonyl halide, such as methyl sulphonyl chloride. Preferably also, the reaction is earned out in the presence of a base, such as triethylamine. Preferably, the reaction is carried out at a temperature of 35°C, or less.

said processing comprising alkylating a compound of Formula (V)
1 6 JUL 2009
20 According to another aspect of the invention there is provided a process for preparing a compound of formula I',

WO 2008/096145

PCT/GB2008/000430


where R constitutes a suitable leaving group, which may not be hydrogen (preferably as described above) with glycine ethyl ester in a suitable solvent, using a base. 5
The compound of formula (I1) may be converted to a salt in the presence of a suitable solvent. Most preferably, the compound of formula (I1) is converted to the hydrochloride salt in a suitable solvent, to obtain compound of Formula (I).
10
The reaction temperature of the alkylation step is preferably 60°C, or lower, more preferably 40°C, or lower.
According to another aspect of the invention there is provided a compound of formula (V): 15

where R is a suitable leaving group, which may not be hydrogen, and is preferably as described above. 20
In another aspect, the present invention provides a process to prepare anagrelide of Formula (II) which comprises the following steps.


WO 2008/096145

PCT/GB2008/000430

8 (i) Forming a salt of the compound of formula I' (the hydrochloride salt is preferred,
formula I) using the process described above; (ii) reducing the nitro group of Formula I with a suitable reducing agent to convert it to an amine of Formula (VI), 5

(iii) reacting the compound of Formula (VI) with a cyanogen halide to form compound of Formula (VII), 10
wherein halide is chloro, bromo or iodo;
(iv) cyclising compound of Formula (VII), to form compound of Formula (II), i.e.
15 anagrelide.
The anagrelide formed by the processes described above may be combined with a suitable carrier to make a pharmaceutical composition. Such compositions may be used to reduce platelet count induced by a variety of aggregating agents. 20
Detailed Description of the invention
The process according to the invention will now be described in more detail below.
25 The process for the preparation of ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride according to the invention is depicted in the reaction scheme below. Brackets indicate intermediates that could be isolated but are not usually isolated in the integrated process.


WO 2008/096145

PCT/GB2008/000430

Scheme IV

5 wherein R represents a suitable leaving group, wherein R is not hydrogen and preferably has the meaning described above in relation to formula (V)
(i) 2, 3-dichloro-6-nitrobenzaldehyde, of Formula ( III) is reduced to give the corresponding alcohol of Formula IV. The reducing agent is preferably selected from sodium borohydride,
10 potassium borohydride, sodium cyanoborohydride and tetramethyl ammonium borohydride. The reaction is preferably carried out in a solvent, which is preferably a C1 to C6 straight chain or branched chain alcohol, especially methanol, ethanol, isopropanol or n-butanol; or a chlorinated solvent such as chloroform, methylene chloride, carbon tetrachloride, ethylene chloride, with methylene chloride being preferred. The reaction is preferably carried out at a
15 temperature ranging from 0°C to the reflux temperature of the solvent., and the reaction time may vary from 1 to 3 hrs.


WO 2008/096145

PCT/GB2008/000430

10 (ii) According to a particular feature of the present invention, the hydroxymethyl functionality of phenyl methyl alcohol of Formula (IV) is protected with suitable protecting group R (as discussed above in relation to formula (IV) using variety of methods.
5 Various organic or inorganic bases may be employed, such as tri ethyl amine, pyridine or potassium carbonate, with triethylamine being preferred.
For example, one method includes reacting 2,3-dichloro-6-nitro benzyl alcohol - Formula (IV) - with alkyl or aryl sulphonyl halide in the presence of a base, such as triethylamine or the
10 like, preferably at a temperature of 35°C, or less, for a time preferably less than 8 hours. The sulfonyl halide is preferably added to the compound of Formula (IV) over an extended period of time at a temperature of 30°C, or less, with stirring. The reaction is not exothermic, which avoids impurity formation. The organic layer may then be separated, washed with an acid and neutralized with a base, then concentrated to obtain the compound of Formula (V).
15
The alkyl sulphonyl halide is preferably C1 to C6 more preferably C1 to C4 straight or branched chain alkyl. The alkyl sulphonyl halide is most preferably methyl suphonyl halide. In the aryl sulphonyl halide, the preferred aryl groups are phenyl and p-toluyl.
20 Steps (i) and (ii) are preferably carried out without isolating the alcohol of Formula (IV).
(iii) According to yet another embodiment of the present invention the compound of Formula (V) is alkylated with glycineethylester in an organic solvent, such as acetonitrile, using base and a catalyst preferably, dimethyl amino pyridine. Suitable bases for this reaction are
25 carbonates or alkali metal hydroxides, preferably anhydrous potassium carbonate. Typically, the reaction is carried out at a temperature less than or equal to 60°C, more preferably less than or equal to 40°C. After completion of the reaction, the reaction mass is filtered, and concentrated under vacuum to obtain ethyl-N~(2,3-dichloro-6-nitrobenzyl) glycine, which is further converted to hydrochloride salt in suitable organic solvent such as ethyl acetate to
30 obtain ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride, a compound of Formula (I)
In prior art processes, where the leaving group is bromo (e.g. US 5801245, column 5, example 3, lines 6-25 ), the reaction with glycine ethyl ester hydrochloride requires 14 hrs
.16 JUL 2009

WO 2008/096145

PCT/GB2008/000430

11 reflux in THF-triethylamine, which requires further purification by column chromatography. Yield- 87% w/w - Efficiency 60.20%.
In prior art processes, when the leaving group is chloro (e.g. US 2003/0060630, page 5
5 [0040]), the reaction is carried out in high boiling solvent toluene, at 80°C for 24 hrs using
10% w/w cetyltrimethylammonium bromide, which is an expensivecatalyst - Efficiency 66-
71%.
In the process according to the invention, where the leaving group is mesyl or tosyl, for 10 example, the reaction can be carried out at low temperature of 37-40°C in acetonitrile as solvent, potassium carbonate as base and 0.2% w/w dimethyl amino pyridine as catalyst. Due to the low reaction temperature, a relatively small level of impurities are formed giving high yield and purity - Efficiency 75.52%.
15 In another aspect of the present invention, intermediate ethyl-N-(2,3-dichloro-6-nitrobenzyl) glycine hydrochloride of Formula (I), prepared by using process of the present invention, is converted to anagrelide by
(iv) Reducing nitro group of Formula (I) with suitable reducing agent to convert it to amine 20 of Formula (VI). Various methods may be employed to carry out the nitro reduction, such as catalytic hydrogenation or met,?' reduction. Normally catalytic hydrogenation is earned out in the presence of noble metal catalysts, such as palladium, platinum, or Raney Nickel on a carbon support . The source of hydrogen may be hydrogen gas or a hydrogen donating compound such as ammonium formate. Metal reduction may be carried out using tin, iron, or 25 using stannous chloride with an acid .
In the forgoing processes the preferred reduction is metal reduction using stannous chloride and a preferred acid is hydrochloric acid. The reaction is preferably carried out at a temperature of 50°C, or less. After completion of the reaction,the reaction mass is filtered, 30 suspended in water and basified to obtain an amine of Formula (VI).
(v) Reacting the compound of Formula (VI) with cyanogen halide to form the compound of Formula (VII) where the halide is as defined above, i.e., chloro, bromo or iodo. Normally the
.1 6 JUL 2009

WO 2008/096145

PCT/GB2008/000430

12 reaction is earned out using cyanogen bromide in an aprotic inert organic solvent such as toluene, chlorobenzene, xylene, heptane and hexane. A preferred solvent is toluene. A preferred reaction temperature is from 80- 150°C.
5 (vi) Cyclising compound of Formula (VII), to form a compound of Formula (II), i.e. anagrelide. The compound, ethyl-N-(5, 6-dichloro-3,4-dihydro-2(lH) iminoquinazoline-3-acetate hydrobromide of Formula (VII), is readily converted to anagrelide of Formula (II) with an organic base, such as triethylamine or dimethylaniline. The reaction may be carried out in an inert solvent. 10
The intermediate compound of Formula (V) represents a novel compound, per se, and this novel intermediate forms further aspects of the present invention.
In the present invention, the reaction is carried out by protecting the hydroxymethyl 15 functionality of compound of formula (IV). When using methane sulphonyl chloride in methylene chloride, the reaction was less exothermic than in the prior art, and was more controllable with less impurity formation. Overall yield :- 76% ( From compound HI to compound I) with HPLC purity of 98.5%
20 Further details of the invention are given in the examples below. The example are provided for illustration only.
EXAMPLES
25 Example 1
Preparation of 2, 3-dicnloro-6-nitro benzyl methane sulphonate, a compound of formula
(V):
Methylene chloride (2000 ml) and sodium borohydride (120 g) were charged to a clean and dry flask and chilled to 0-5°C. Methanol (100 ml) was added slowly over a period of 20 30 minutes followed by 2,3-dichloro-6-nitro benzaldehyde solution (500 g in 2000 ml of methylene chloride) over a period of 2 hours maintaining the temperature at 0-5°C and the contents were stirred at 0-5°C for 1 hour. After completion of reaction, water (3000 ml) was
1 6 JUL 2009

WO 2008/096145

PCT/GB2008/000430

13
added and stirred for 10 minutes. The organic layer was separated, dried over sodium sulphate and was filtered to get a clear filtrate.
To the clear filtrate triethylamine (460 ml), was slowly added over a period of 1 hour at 10-5 15°C, then methane sulphonyl chloride (325 ml) was added drop wise over a period of 2 hours maintaining temperature of 10-15°C and the reaction mass was allowed to attain room temperature. Further the reaction mass was stirred at room temperature for 5 hours and after completion of reaction, the organic layer was washed with water (1000 ml) twice, followed by IN HC1 solution (1000 ml) twice, 5% Sodium bicarbonate solution (1000 ml) twice, water 10 (1000 ml) twice and was dried over sodium sulfate. The clear organic layer was concentrated under vacuum below 40°C to give the title compound which was used in the next step.
Example 2
Preparation of ethyl N-(2,3-dichloro-6-nitrobenzyl)gIycine hydrochloride, a compound of 15 formula (I):
2,3-dichloro-6-nitro benzyl methane sulphonate ( Examplel ) was dissolved in acetonitrile (2400 ml). To this reaction mass were charged anhydrous Potassium carbonate (480 g), dimethyl amino pyridine (480 mg) and glycine ethyl ester (240 g) at room temperature. The contents were stirred at 37-40°C for 24 hours. After completion of reaction, the insolubles 20 were filtered, washed with acetonitrile (120 ml). The clear filtrate was concentrated and stripped off usinp ethyl acetate (240 ml).
Further ethyl acetate (1200 ml) was added, chilled the contents to 5-10°C, adjusted the pH to 2.0 using IPA-HC1 at 5-10°C. The contents were stirred at 5-10°C for 1 hour. The solids were 25 filtered, washed with chilled ethyl acetate (120 ml) and dried under vacuum at room temperature for 4 hours to give the title compound (595 g, 76 % yield, 98.5% HPLC purity).
Example 3
Preparation of Anagrelide , a compound of formula (II) 30
a) Preparation of Ethyl-5,6-dichloro-3,4-dihydro-2[lH]-imino quinazoIin-3-acetate hydrobromide
16 JUL 2009

WO 2008/096145

PCT/GB2008/000430

14 A solution of stannous chloride dihydrate (1850 gms) in concentrated HC1 (6.7 liters ) was added slowly to a cooled solution of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride (595gms) in concentrated HC1 (5.15 liters) maintaining temperature 15-20°C over a period of 2 hours. The contents were heated slowly to 40-45 °C and stirred for 1 hour at 5 40-45°C. After completion of reaction, the contents were cooled to 15-20°C, maintained for 15 minutes and filtered.
The solids thus obtained were suspended in water (2.9 liters), adjusted the pH of the reaction mass to 8.0-9.0 using potassium carbonate solution (prepared by dissolving 376 gms of 10 potassium carbonate in 4.25 liters of water) at 0-5°C, extracted into toluene (3.0 liters><3), dried over sodium sulphate and clarified.
To the clear toluene layer, added Cyanogen bromide solution (prepared by dissolving 222 gms of cyanogen bromide in 655 ml of toluene) in 30 minutes maintaining temperature 15-20°C
15 and stirred at 25-30°C for 2 hours. The contents were heated slowly to 105-110°C and maintained for 16 hours at 105-110°C. After completion of reaction, the mass was cooled to 15-20°C and stirred for 45 minutes. Filtered the material, washed with chilled toluene (1.3 liters). The material was slurried in toluene (470 ml) at 15-20°C for 1 hour, filtered, washed with cold toluene (160 ml) and dried under vacuum at 50-60°C for 8 hours to give the title
20 compound (445 gms ).
b) Preparation of 6,7-Dichloro-l,5-dihydroimidazo[2,l-b]quinazoIin-2(3H)-one [Anagrelide]
A mixture of ethyl-5,6-dichloro-3,4-dihydro-2(lH)-iminoquinazolin-3-acetate hydrobromide
25 (445 gms), isopropyl alcohol (4.45 liters) and triethylamine (246 ml) was refluxed for 2
hours. After completion of reaction, the mixture was cooled to 20-25°C, filtered, washed with chilled isopropyl alcohol (1.0 liters) and dried under vacuum at 50-55°C for 6 hours to give the title compound (285 gms).
30 It will be appreciated that the invention described above may be modified within the scope of the claims.
,16 JUL 2009

WO 2008/096145

PCT/GB2008/000430

15 CLAIMS:
]. A process for the synthesis of a compound of Formula (V)

5 where R is a suitable leaving group, which may not be hydrogen, said process comprising reacting a compound of formula (IV)

10 with suitable compound to obtain the compound of Formula (V).
2. A process according to claim 1, wherein the reaction is earned out in the presence of an alkyl or aryl sulphonyl halide.
15 3 A process according to claim 1 or 2, wherein the r action is carried out in the presence
of a base.
4. A process according to claim 1, 2 or 3, wherein the reaction is carried out at a
temperature of 35°C, or less.
20
5. A process according to any preceding claim, wherein the compound of formula IV is
prepared by reducing a compound of formula (III):
.16 JUL 2009

WO 2008/096145 PCT/GB2008/000430

6. A process according to claim 5, wherein the compound of formula V is prepared from
the compound of formula (III) without isolation of the compound of formula (IV).
5
7. A process for preparing a compound of formula I',

said processing comprising alkylating a compound of Formula (V)

where R constitutes a suitable leaving group, which may not be hydrogen, with glycine ethyl ester in a suitable solvent, using a base.
15 8. A process according to claim 7, comprising converting the compound of formula (I') to
a salt in the presence of a suitable solvent.
9. A process according to claim 7, comprising converting the compound of formula (I') to
the hydrochloride salt in a suitable solvent, to obtain compound of Formula (I).
20


WO 2008/096145

PCT/GB2008/000430

17
10. A process according to any one of claims 7, 8 or 9, wherein the reaction temperature of
the alkylation step is 60°C, or lower.
11. A process according to any one of claims 7, 8 or 9, wherein the reaction temperature of
5 the alkylation step is 40°C, or lower.
12. A process according to any one of claims 7, 8, 9 or 10, wherein the compound of
formula (V) is prepared by a process according to any one of claims 1 to 6.
10 13. A process for preparing anagrelide of Formula (II), which comprises:
(i) preparing a compound of formula (I) by a process according to any one of
claims 7 to 12;
(ii) reducing the nitro group of Formula (I) with a suitable reducing agent to
15 convert it to an amine of Formula (VI),

(iii) reacting the compound of Formula (VI) with a cyanogen halide to form
20 compound of Formula (VII).

wherein halide is chloro, bromo or iodo; and
25 (iv) cyclising compound of Formula (VII), to form compound of Formula (II).


WO 2008/096145

PCT/GB2008/000430

14. A process according to any one of the preceding claims, wherein the group R is -SiR^, where R1 is a substituted or unsubstituted alkyl. R is preferably C1 to C6, more preferably Ci to C4 straight or branched chain alkyl group. Most preferably R1 is methyl.
5 15. A process according to any one of claims 1 to 13, wherein the group R is-CH2Ar, where Ax stands for aryl, preferably a substituted or unsubstituted phenyl group.
16. A process according to any one of claims 1 to 13, wherein the group R is -COOR2, where R is alkyl or aryl.
10
17. A process according to claim 16, wherein R is methyl.
18. A process according to any one of claims 1 to 13, wherein the group R is -SO2R3,
where R is alkyl or aryl.
15
19. A process according to claim 18, wherein the group -OR is mesylate, besylate or
tosylate.
20. A compound of formula (V): 20

where R is a suitable leaving group, which may not be hydrogen.
25 21. A compound according to claim 20, wherein the group R is -SiR'3, where R1 is a substituted or unsubstituted alkyl. R1 is preferably C1 to C6, more preferably C1 to C4 straight or branched chain alkyl group. Most preferably R' is methyl.


WO 2008/096145 PCT/GB2008/000430
19
22. A compound according to claim 20, wherein the group R is-CH2Ar, where Ar stands
for aryl, preferably a substituted or unsubstituted phenyl group.
23. A compound according to claim 20, wherein the group R is -COOR2, where R2 is 5 alkyl or aryl.
24. A compound according to claim 23, wherein R2 is methyl.
25. A compound according to claims 20, wherein the group R is -SO2R , where R is alkyl
10 or aryl.
26. A compound according to claim 25, wherein the group OR is mesylate, besylate or
tosylate.
16 JUL 2009

Documents

Application Documents

# Name Date
1 1345-MUMNP-2009-ABSTRACT(18-3-2010).pdf 2018-08-10
1 1345-MUMNP-2009-RECEIPT(IPO)-(16-11-2009).pdf 2009-11-16
2 1345-MUMNP-2009-ANNEXURE TO FORM 3(11-1-2010).pdf 2018-08-10
2 1345-MUMNP-2009-CORRESPONDENCE(16-11-2009).pdf 2009-11-16
3 Other Document [11-01-2017(online)].pdf 2017-01-11
3 1345-mumnp-2009-claims.doc 2018-08-10
4 Examination Report Reply Recieved [11-01-2017(online)].pdf 2017-01-11
4 1345-mumnp-2009-claims.pdf 2018-08-10
5 Description(Complete) [11-01-2017(online)].pdf_356.pdf 2017-01-11
5 1345-MUMNP-2009-CORRESPONDENCE(1-2-2011).pdf 2018-08-10
6 Description(Complete) [11-01-2017(online)].pdf 2017-01-11
6 1345-MUMNP-2009-CORRESPONDENCE(10-9-2009).pdf 2018-08-10
7 Claims [11-01-2017(online)].pdf 2017-01-11
7 1345-MUMNP-2009-CORRESPONDENCE(11-1-2010).pdf 2018-08-10
8 1345-MUMNP-2009-RELEVANT DOCUMENTS [23-03-2018(online)].pdf 2018-03-23
8 1345-MUMNP-2009-CORRESPONDENCE(18-3-2010).pdf 2018-08-10
9 1345-MUMNP-2009-CORRESPONDENCE(IPO)-(13-4-2017).pdf 2018-08-10
9 abstract1.jpg 2018-08-10
10 1345-MUMNP-2009-CORRESPONDENCE-011015.pdf 2018-08-10
10 1345-mumnp-2009-wo international publication report a1.pdf 2018-08-10
11 1345-mumnp-2009-correspondence.pdf 2018-08-10
11 1345-MUMNP-2009-POWER OF AUTHORITY(10-9-2009).pdf 2018-08-10
12 1345-mumnp-2009-pct-ib-308.pdf 2018-08-10
13 1345-mumnp-2009-description(complete).pdf 2018-08-10
13 1345-mumnp-2009-pct-ib-304.pdf 2018-08-10
14 1345-MUMNP-2009-FER.pdf 2018-08-10
14 1345-MUMNP-2009-PatentCertificateCoverLetter.pdf 2018-08-10
15 1345-mumnp-2009-form 1.pdf 2018-08-10
15 1345-MUMNP-2009-MARKED COPY-011015.pdf 2018-08-10
16 1345-MUMNP-2009-Form 13-011015.pdf 2018-08-10
16 1345-MUMNP-2009-GENERAL POWER OF AUTHORITY-011015.pdf 2018-08-10
17 1345-MUMNP-2009-FORM NO.INC-22-011015.pdf 2018-08-10
17 1345-MUMNP-2009-FORM 18(1-2-2011).pdf 2018-08-10
18 1345-mumnp-2009-form 5.pdf 2018-08-10
18 1345-mumnp-2009-form 2(title page).pdf 2018-08-10
19 1345-mumnp-2009-form 3.pdf 2018-08-10
20 1345-mumnp-2009-form 2.pdf 2018-08-10
21 1345-mumnp-2009-form 3.pdf 2018-08-10
22 1345-mumnp-2009-form 2(title page).pdf 2018-08-10
22 1345-mumnp-2009-form 5.pdf 2018-08-10
23 1345-MUMNP-2009-FORM 18(1-2-2011).pdf 2018-08-10
23 1345-MUMNP-2009-FORM NO.INC-22-011015.pdf 2018-08-10
24 1345-MUMNP-2009-Form 13-011015.pdf 2018-08-10
24 1345-MUMNP-2009-GENERAL POWER OF AUTHORITY-011015.pdf 2018-08-10
25 1345-MUMNP-2009-MARKED COPY-011015.pdf 2018-08-10
25 1345-mumnp-2009-form 1.pdf 2018-08-10
26 1345-MUMNP-2009-PatentCertificateCoverLetter.pdf 2018-08-10
26 1345-MUMNP-2009-FER.pdf 2018-08-10
27 1345-mumnp-2009-description(complete).pdf 2018-08-10
27 1345-mumnp-2009-pct-ib-304.pdf 2018-08-10
28 1345-mumnp-2009-pct-ib-308.pdf 2018-08-10
29 1345-mumnp-2009-correspondence.pdf 2018-08-10
29 1345-MUMNP-2009-POWER OF AUTHORITY(10-9-2009).pdf 2018-08-10
30 1345-MUMNP-2009-CORRESPONDENCE-011015.pdf 2018-08-10
30 1345-mumnp-2009-wo international publication report a1.pdf 2018-08-10
31 1345-MUMNP-2009-CORRESPONDENCE(IPO)-(13-4-2017).pdf 2018-08-10
31 abstract1.jpg 2018-08-10
32 1345-MUMNP-2009-CORRESPONDENCE(18-3-2010).pdf 2018-08-10
32 1345-MUMNP-2009-RELEVANT DOCUMENTS [23-03-2018(online)].pdf 2018-03-23
33 Claims [11-01-2017(online)].pdf 2017-01-11
33 1345-MUMNP-2009-CORRESPONDENCE(11-1-2010).pdf 2018-08-10
34 Description(Complete) [11-01-2017(online)].pdf 2017-01-11
34 1345-MUMNP-2009-CORRESPONDENCE(10-9-2009).pdf 2018-08-10
35 Description(Complete) [11-01-2017(online)].pdf_356.pdf 2017-01-11
35 1345-MUMNP-2009-CORRESPONDENCE(1-2-2011).pdf 2018-08-10
36 Examination Report Reply Recieved [11-01-2017(online)].pdf 2017-01-11
36 1345-mumnp-2009-claims.pdf 2018-08-10
37 Other Document [11-01-2017(online)].pdf 2017-01-11
38 1345-MUMNP-2009-CORRESPONDENCE(16-11-2009).pdf 2009-11-16
38 1345-MUMNP-2009-ANNEXURE TO FORM 3(11-1-2010).pdf 2018-08-10
39 1345-MUMNP-2009-ABSTRACT(18-3-2010).pdf 2018-08-10
39 1345-MUMNP-2009-RECEIPT(IPO)-(16-11-2009).pdf 2009-11-16

ERegister / Renewals

3rd: 14 Jun 2017

From 06/02/2010 - To 06/02/2011

4th: 14 Jun 2017

From 06/02/2011 - To 06/02/2012

5th: 14 Jun 2017

From 06/02/2012 - To 06/02/2013

6th: 14 Jun 2017

From 06/02/2013 - To 06/02/2014

7th: 14 Jun 2017

From 06/02/2014 - To 06/02/2015

8th: 14 Jun 2017

From 06/02/2015 - To 06/02/2016

9th: 14 Jun 2017

From 06/02/2016 - To 06/02/2017

10th: 14 Jun 2017

From 06/02/2017 - To 06/02/2018

11th: 25 Jan 2018

From 06/02/2018 - To 06/02/2019